Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT03606174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03606174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 11, 2018
Completion date
August 22, 2022
Enrollment
260 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma, urothelial carcinoma bladder, urothelial carcinoma of the renal pelvis and ureter, urothelial carcinoma ureter, urothelial carcinoma urethra